The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 3-22, January 2003

Update on glucocorticoid action and resistance

Denver, Colo, and Tucson, Ariz

From athe Division of Pediatric Allergy/Immunology, National Jewish Medical and Research Center, Denver; bthe Department of Pediatrics, University of Colorado Health Sciences Center, Denver; and cthe Departments of Pharmacology and Medicine, Arizona Respiratory Center, University of Arizona and College of Medicine, Tucson

Received 23 October 2002; accepted 23 October 2002.

Abstract 

Continuing Medical Education examination

CONTINUING MEDICAL EDUCATION ARTICLE Credit can now be obtained, free for a limited time, by reading the following review. Please note the instructions listed below. Method of Physician Participation in Learning Process: The core material for this activity can be read in this issue of the Journal or online at the JACI Web site: www.mosby.com/jaci . The accompanying test may only be submitted online at www.mosby.com/jaci . Fax or other copies will not be accepted. Date of Original Release: January 2003. Credit may be obtained for this course until December 31, 2003. Copyright Statement: Copyright © 2003-2004. All rights reserved. List of Design Committee Members: Authors: Donald Y. M. Leung, MD, PhD, FAAAAI, John W. Bloom, MD Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Activity Objectives (a) To understand the molecular mechanisms of glucocorticoid action. (b) To recognize potential mechanisms of glucocorticoid resistance. (c) To review evaluation and management of patients with glucocorticoid resistance. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this educational activity for up to 1.0 hour in Category I credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit he or she actually spent in the educational activity. Recognition of Commercial Support: This activity has been funded through an unrestricted educational grant from GlaxoSmithKline.

Keywords:  Asthma, steroid-resistant asthma, glucocorticoid, T cells

Abbreviations:  AP-1 , Activator protein 1, BAL , Bronchoalveolar lavage, CBP , CREB-binding protein, GC , Glucocorticoid, GR , Glucocorticoid receptor, GRE , Glucocorticoid response element, HAT , Histone acetyltransferase, HDAC , Histone deacetylase, hsp 90 , Heat shock protein 90, ICAM-1 , Intercellular adhesion molecule 1, IκB , Inhibitory κB, MAP , Mitogen-activated protein, NFκB , Nuclear factor κB, NL , Nuclear localization signal, NO , Nitric oxide, NP , Nasal polyp, SEB , Staphylococcal enterotoxin B, SRC , Steroid receptor coactivator, STAT , Signal transducer and activator of transcription, Swi/Snf , Switch/sucrose nonfermentable, UC , Ulcerative colitis, VCAM-1 , Vascular cell adhesion molecule

 

 Reprint requests: Donald Y. M. Leung, MD, PhD, National Jewish Medical and Research Center, 1400 Jackson St, Room K926, Denver, CO 80206.

PII: S0091-6749(02)91359-X

doi:10.1067/mai.2003.97

The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 3-22, January 2003